TMDX

TransMedics Group Inc

TMDX, USA

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.

https://www.transmedics.com

Stock Price

$ 0.00

0% decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
TMDX
stock
TMDX

(TMDX) Movement Within Algorithmic Entry Frameworks news.stocktradersdaily.com

Read more →
TMDX
stock
TMDX

Reasons to retain TransMedics stock in your portfolio for now MSN

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$143

Analyst Picks

Strong Buy

5

Buy

1

Hold

3

Sell

0

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

55.16

Low ≥ 50

High ≤ 10

Price to Book Ratio (P/B)

-

Very High

14.55

Low ≤ 1

High ≥ 3

Return on Equity (ROE)

-

Very Low

6.85 %

Low ≤ 5%

High ≥ 25%

Return on Assets (ROA)

-

Very Low

2.57 %

Low ≤ 2%

High ≥ 10%

Free Cash Flow - Revenue % (FCF)

-

Very High

43.07 %

Low ≤ 5%

High ≥ 15%

Debt to Equity

-

Very Low

1.66

Low ≥ 1

High ≤ 0.3

Investors

* Institutions hold a combined 107.81% of the total shares of TransMedics Group Inc

1.

BlackRock Inc

(15.3229%)

since

2025/06/30

2.

FMR Inc

(14.7365%)

since

2025/06/30

3.

Vanguard Group Inc

(10.5483%)

since

2025/06/30

4.

iShares Core S&P Small-Cap ETF

(5.9019%)

since

2025/08/31

5.

State Street Corp

(3.7812%)

since

2025/06/30

6.

Fidelity International Ltd

(3.0963%)

since

2025/06/30

7.

Vanguard Total Stock Mkt Idx Inv

(2.9556%)

since

2025/07/31

8.

UBS Asset Mgmt Americas Inc

(2.8034%)

since

2025/06/30

9.

Macquarie Group Ltd

(2.7929%)

since

2025/06/30

10.

Driehaus Capital Management LLC

(2.5052%)

since

2025/06/30

11.

Geode Capital Management, LLC

(2.3603%)

since

2025/06/30

12.

iShares Russell 2000 ETF

(2.3529%)

since

2025/08/31

13.

Vanguard Small Cap Index

(2.2876%)

since

2025/07/31

14.

Morgan Stanley - Brokerage Accounts

(2.1496%)

since

2025/06/30

15.

Hood River Capital Management LLC

(1.9943%)

since

2025/06/30

16.

Fidelity

(1.895%)

since

2025/06/30

17.

Fidelity Small Cap Growth

(1.8588%)

since

2025/06/30

18.

Macquarie Small Cap Core I

(1.6754%)

since

2025/07/31

19.

Fidelity Advisor New Insights I

(1.6075%)

since

2025/07/31

20.

Eventide Asset Management, LLC

(1.6056%)

since

2025/06/30

21.

Marshall Wace Asset Management Ltd

(1.6039%)

since

2025/06/30

22.

Liontrust Investment Partners LLP

(1.5364%)

since

2025/06/30

23.

Amvescap Plc.

(1.3983%)

since

2025/06/30

24.

UBS Group AG

(1.3967%)

since

2025/06/30

25.

JPMorgan Chase & Co

(1.3618%)

since

2025/06/30

26.

Eventide Gilead N

(1.3514%)

since

2025/06/30

27.

Brown Capital Management, LLC

(1.324%)

since

2025/06/30

28.

Vanguard Small Cap Growth Index Inv

(1.2913%)

since

2025/07/31

29.

Emerald Advisers, LLC

(1.2887%)

since

2025/06/30

30.

Two Sigma Investments LLC

(1.2085%)

since

2025/06/30

31.

Fidelity VIP Contrafund Initial

(1.2021%)

since

2025/07/31

32.

Hood River Small-Cap Growth Instl

(1.072%)

since

2025/06/30

33.

Vanguard Institutional Extnd Mkt Idx Tr

(1.0671%)

since

2025/07/31

34.

Fidelity OTC

(1.0669%)

since

2025/07/31

35.

Fidelity Small Cap Index

(0.9786%)

since

2025/06/30

36.

Fidelity VIP Mid Cap Initial

(0.9475%)

since

2025/07/31

37.

Fidelity Small Cap Growth K6

(0.8943%)

since

2025/06/30

39.

iShares Russell 2000 Growth ETF

(0.858%)

since

2025/08/31

40.

iShares S&P Small-Cap 600 Growth ETF

(0.854%)

since

2025/08/31

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

0.3826

Latest Release

Date

2025-09-30

EPS Actual

0.66

EPS Estimate

0.36

EPS Difference

0.3

Surprise Percent

83.3333%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(5.5)
Dividend
Weak Dividend Profile(3)
Economic Moat
Wide Moat Company(7.3)
GARP
Not Attractive for GARP(3)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(4)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
High Quality(7)
Value
Fair Value(4)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.